China’s vaccine landscape is shifting after local biotech Xiamen Innovax Biotech unveiled the country’s first domestically ...

Merck issued guidance for 2025 that lags consensus amid struggles in China with Gardasil Merck's stock tumbled 11.8% Tuesday, putting it on track for its biggest one-day selloff in almost 17 years ...

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts.

But Merck's vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., posted another quarter of lighter-than-expected sales.

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations, as the company temporarily paused shipments of a key vaccine into China.

In Q2, the revenue generated by Merck's HPV vaccine, Gardasil, increased just 1% versus the same period a year earlier to $2.48 billion. The company blamed the "timing of shipments" in China.